Knome Gets $5M From bioMérieux
Knome, a Cambridge, MA-based genomics sequencing and analysis company, received $5 million from France’s bioMérieux in exchange for an equity stake. It’s part of a partnership deal in which the French company will use Knome’s technology to develop in vitro diagnostics for cancer and infectious diseases, the companies announced today. As part of the deal, bioMérieux will appoint its CEO Stéphane Bancel as a director on the Knome board. Ryan profiled Knome in January.